Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of POL7080 for acute exacerbation of non-cystic fibrosis bronchiectasis caused by Pseudomonas aeruginosa
2013-002202-31Phase 2Completed
- Sponsor
- Polyphor
- Start
- Jun 2013
- Modality
- Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of murepavadin in bronchiectasis and Pseudomonal infection, sponsored by Polyphor. Primary endpoint: Sputum bacterial clearance. Started Jun 2013; status: completed.
02
Drugs
murepavadin
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on 2013-002202-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002202-31.